Terveystalo came into this Q3 2026 print as a classic recovery story on paper, yet with a share price that has been grinding lower. The stock closed at €5.96 on 23 October and has fallen over the past week and month, so expectations were already soft.
The headline result then landed with a thud. Third quarter revenue came in at €263.2m and net income at €5.5m, far below the earnings power suggested by earlier quarters. You saw that disconnect play out in real time as a market that once paid up for a healthcare efficiency story now prices in margin pressure and patience fatigue.
Interested in Terveystalo as a recovery idea but uncomfortable with earnings that look fragile and margins under strain? Compare it with a list of solid balance sheet and fundamentals stocks (205 results) to identify healthcare players in which balance sheet strength and fundamentals carry more of the weight.
Q3 2026 Earnings Summary
-
Revenue (Q3 2026 vs. Q3 2025):€263.2m vs. €280.4m (declined 6.1%)
-
Net Income (Q3 2026 vs. Q3 2025):€5.5m vs. €16.2m (fell 66.0%)
-
Basic EPS (Q3 2026 vs. Q3 2025):€0.04 vs. €0.13 (down 68.7%)
-
Trailing 12-Month Net Profit Margin (latest vs. prior year):4.8% vs. 7.0% (compressed 2.2 percentage points)
Prefer clear visuals over scrolling through dense financial tables and raw figures? View Terveystalo Oyj's full financial picture in an easy chart-based format that highlights its recent earnings and profitability trends in the company report for Terveystalo Oyj.
Terveystalo bull case meets softer demand reality
The upbeat story assumes new initiatives will steadily lift volumes and upgrade the mix for Terveystalo.
"Expansion into new public and private healthcare initiatives, as well as high-demand segments, positions the company for sustainable revenue growth and margin enhancement."
Q3 tells a tougher story. Total revenue fell 6.1% and net income declined 66.0%, so neither growth nor profitability moved in the direction that narrative implies. Dental, helped by the Hohde acquisition, was the clear bright spot, yet weakness in occupational health, portfolio outsourcing and muted Sweden demand outweighed that progress.
Bear case on concentration and contracts gains traction
The main worry is that heavy Finnish exposure and contract churn could chip away at both the top line and profitability.
"Loss and termination of some outsourcing and corporate contracts, along with greater volatility and reduced public sector outsourcing volumes due to well-being counties ramping up in-house operations, suggest that revenue from portfolio businesses is at risk and net margin improvements may not be sustainable if volume weakness persists."
Q3 outcomes lean in that direction. Outsourcing revenue in the portfolio businesses segment declined as expected and contributed to weaker EBIT. Trailing 12-month net margin compressed from 7.0% to 4.8%, which indicates that contract and volume pressure has already started to erode profitability.
That disagreement has a full argument behind it. → Uncover the higher Fair Value this Narrative argues for .
Hunt For Mispriced Recoveries
Terveystalo Oyj just showed how a recovery story on paper can clash with softer reported earnings. The real opportunity is finding stocks that could be undervalued before the market recognizes their progress.
-
Company 1 - 38% below our estimate - uses a unified operating platform to cut costs and expand higher-margin fee and digital payment services.
-
Company 2 - 41% below our estimate - turns a capacity increase and refreshed model lineup into greater export volumes for light commercial vehicles.
-
Company 3 - 42% below our estimate - builds complex-care hospitals and applies AI tools to operate higher-acuity facilities with improved efficiency.
Three companies from the same screener. Open all 201 potentially undervalued companies →
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include TTALO.HE .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
